Anorexigenic Effects of Miglitol in Concert with the Alterations of Gut Hormone Secretion and Gastric Emptying in Healthy Subjects

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Hormone and Metabolic Research

• Publication date

  2012-02-20

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1055/s-0032-1304563PMID 22351480
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased suppression of serum ghrelin concentration by hyperinsulinemia in women with anorexia nervosa.

  2010cited by this paper
• (13)C-octanoic acid breath test (OBT) with a new test meal (EXPIROGer): Toward standardization for testing gastric emptying of solids.

  2010cited by this paper
• Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes.

  2010cited by this paper
• Ghrelin and PYY in the regulation of energy balance and metabolism: lessons from mouse mutants.

  2010cited by this paper
• Gut hormones and appetite control.

  2009cited by this paper
• Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man.

  2009cited by this paper
• GOAT links dietary lipids with the endocrine control of energy balance

  2009cited by this paper
• Gut hormones and appetite control.

  2007cited by this paper
• Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1

  2007cited by this paper
• Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation

  2006cited by this paper
• Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia.

  2006cited by this paper
• alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.

  2005cited by this paper
• α‐Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon‐like peptide 1 (7–36 amide) and to delay gastric emptying in Type 2 diabetic patients

  2005cited by this paper
• Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ

  2004cited by this paper
• The effects of miglitol on glucagon‐like peptide‐1 secretion and appetite sensations in obese type 2 diabetics

  2002cited by this paper
• Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects.

  2002cited by this paper
• Insulin regulates plasma ghrelin concentration.

  2002cited by this paper
• Gut hormone PYY3-36 physiologically inhibits food intake

  2002cited by this paper
• Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats.

  2002cited by this paper
• A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans.

  2001cited by this paper
• Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.

  2001cited by this paper
• The use of visual analogue scales to assess motivation to eat in human subjects: a review of their reliability and validity with an evaluation of new hand-held computerized systems for temporal tracking of appetite ratings

  2000cited by this paper
• Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans.

  2000cited by this paper
• Ghrelin is a growth-hormone-releasing acylated peptide from stomach

  1999cited by this paper
• Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.

  1998cited by this paper
• Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti‐hyperglycaemic effect

  1998cited by this paper
• Prolonged and enhanced secretion of glucagon‐like peptide 1 (7‐36 amide) after oral sucrose due to α‐glucosidase inhibition (acarbose) in Type 2 diabetic patients

  1998cited by this paper
• A role for glucagon-like peptide-1 in the central regulation of feeding

  1996cited by this paper
• Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.

  1995cited by this paper
• Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose).

  1995cited by this paper
• Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve.

  1995cited by this paper
• Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36.

  1994cited by this paper
• Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test.

  1993cited by this paper
• Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion.

  1992cited by this paper
• Effects of α‐Glucosidase Inhibition and Viscous Fibre on Diabetic Control and Postprandial Gut Hormone Responses

  1990cited by this paper
• Human distribution and release of a putative new gut hormone, peptide YY.

  1985cited by this paper

• Insulin Resistance Is Better Estimated by Using Fasting Glucose, Lipid Profile, and Body Fat Percent Than by HOMA-IR in Japanese Patients with Type 2 Diabetes and Impaired Glucose Tolerance: An Exploratory Study

  2024cites this paper
• Antidiabetic Potential and Chronic Toxicity of Hydroalcoholic Extract of Echeveria subrigida Leaves

  2023cites this paper
• Callyspongia spp.: Secondary Metabolites, Pharmacological Activities, and Mechanisms

  2023cites this paper
• Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes

  2020cites this paper
• Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones.

  2019cites this paper
• Appetite and Gut Hormones Response to a Putative α-Glucosidase Inhibitor, Salacia Chinensis, in Overweight/Obese Adults: A Double Blind Randomized Controlled Trial

  2017influential citation
• Efficacy and safety of combination therapy with an α‐glucosidase inhibitor and a dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta‐analysis

  2017cites this paper
• Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study

  2015cites this paper
• Postprandial effects of a polyphenolic grape extract (PGE) supplement on appetite and food intake: a randomised dose-comparison trial

  2015cites this paper
• Review: Miglitol has potential as a therapeutic drug against obesity

  2015cites this paper
• Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels.

  2014cites this paper
• Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of Sodium Glucose Transporters SGLT1 and SGLT2, in Type 2 Diabetes on Metformin Monotherapy

  2014cites this paper
• Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".

  2014cites this paper
• Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy

  2014cites this paper
• メタボリックシンドロームを合併した日本人2型糖尿病の特徴とその予防(メタボリックシンドロームの治療の進歩,2012年,第53回日本心身医学会総会ならびに学術講演会(鹿児島))

  2013cites this paper